TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Dose Finding Study in 4 Parallel Groups to Establish the Efficacy and Safety of an Eight Week Treatment With Itopride Three Times Daily Compared to Placebo in Patients Suffering From Functional Dyspepsia
Brief Summary: This study aims to determine the efficacy and optimal dose of the prokinetic itopride for the treatment of patients with functional dyspepsia.

The study will test in patients with functional dyspepsia the hypothesis that itopride is superior to placebo with regard to the improvement of symptoms.


Options:
A: Intervention Type: DRUG; Name: Itopride (drug); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Cinitapride | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: domperidone | Intervention Type: DRUG; Name: Cinitapride; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: domperidone; Assigned to Arm(s): 2
D: Arm Label: Z-338; Type: EXPERIMENTAL; Interventions: Drug: Z-338 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Z-338; Assigned to Arm(s): Z-338 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Zinc and Vitamin A Supplementation on Diarrhea, Physical Growth and Immune Response in Malnourished Children
Brief Summary: Zinc deficiency is common in developing country children, as food intakes are often low, foods from animal sources are infrequently used, the bioavailability of zinc from staple cereal-based diets is limited and zinc losses occur during recurring diarrheal illnesses. Zinc deficiency is associated with impairment in immunological and other defenses against infection and increased rates of serious infections. Due to limitations in currently used biochemical markers, supplementation trials in populations likely to be deficient provide a reliable means of assessing health consequences of zinc deficiency.

A significantly lower incidence and prevalence of diarrhea has been observed in zinc supplemented developing country children in several placebo-controlled trials. The effect of routine zinc supplementation on lower respiratory tract infection is still unclear. We, therefore, evaluated the impact of daily zinc supplementation in a representative sample of children aged 6 to 30 months enrolled from a New Delhi slum area, with a sample size sufficient to determine the impact on the incidence of severe diarrhea and acute lower respiratory infection.


Options:
A: Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Micronutrient (Zinc and Iron) fortification; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Pre and Probiotic fortification; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Zinc and vitamin A single dose at enrollment | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo and vitamin A single dose at enrollment | Intervention Type: DRUG; Name: Zinc and vitamin A single dose at enrollment; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo and vitamin A single dose at enrollment; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Zinc Supplementation in Low Birth Weight Infants on Severe Morbidity, Mortality and Zinc Status: A Randomized Controlled Trial
Brief Summary: There are currently no interventions available to substantially reduce the incidence of low birth weight (LBW) apart from increasing the age at marriage, maternal iron supplementation and possibly improved energy intakes.

The current view of the medical and public health community in India is that the immediate focus should be on promoting survival and development of low birth weight infants who have nearly a 6 to 7 fold higher mortality during infancy than those with normal birth weight.

Low serum zinc is associated with increased incidence of diarrhea and pneumonia. There is sufficient evidence in under-threes that during acute illness, zinc supplementation (1-2 recommended dietary allowance \[RDA\]) reduces incidence of all episodes of diarrhea, severe diarrhea and pneumonia. A number of initial published trials also show significant effect of zinc treatment on pneumonia. With the large and consistent effects of zinc supplementation on the incidence and severity of infections, an effect on child mortality is likely.

Available literature suggests the distinct possibility of reduced neonatal and infant mortality in LBWs receiving 1 RDA of zinc daily. A pilot study in India showed a 54% reduction in mortality in LBW infants. These findings were based on a very small sample and therefore considered insufficient to change policy.

A positive impact in the proposed study will provide an important tool for reduction of infant mortality which is currently stagnant and government acceptance for such a program is likely to be very high. We, the researchers at the Society for Applied Studies, believe this study has the potential for decreasing infant mortality from its current level.


Options:
A: Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: ZINC; Assigned to Arm(s): N/A
C: Arm Label: Fe, Zn, Fe+Zn, Placebo; Type: N/A; Interventions: N/A
D: Arm Label: Zinc; Type: EXPERIMENTAL; Interventions: Drug: Drug: Zinc (zinc sulphate) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Drug: Zinc (zinc sulphate); Assigned to Arm(s): Zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Zinc Supplementation in Low Birth Weight Infants on Severe Morbidity, Mortality and Zinc Status: A Randomized Controlled Trial
Brief Summary: There are currently no interventions available to substantially reduce the incidence of low birth weight (LBW) apart from increasing the age at marriage, maternal iron supplementation and possibly improved energy intakes.

The current view of the medical and public health community in India is that the immediate focus should be on promoting survival and development of low birth weight infants who have nearly a 6 to 7 fold higher mortality during infancy than those with normal birth weight.

Low serum zinc is associated with increased incidence of diarrhea and pneumonia. There is sufficient evidence in under-threes that during acute illness, zinc supplementation (1-2 recommended dietary allowance \[RDA\]) reduces incidence of all episodes of diarrhea, severe diarrhea and pneumonia. A number of initial published trials also show significant effect of zinc treatment on pneumonia. With the large and consistent effects of zinc supplementation on the incidence and severity of infections, an effect on child mortality is likely.

Available literature suggests the distinct possibility of reduced neonatal and infant mortality in LBWs receiving 1 RDA of zinc daily. A pilot study in India showed a 54% reduction in mortality in LBW infants. These findings were based on a very small sample and therefore considered insufficient to change policy.

A positive impact in the proposed study will provide an important tool for reduction of infant mortality which is currently stagnant and government acceptance for such a program is likely to be very high. We, the researchers at the Society for Applied Studies, believe this study has the potential for decreasing infant mortality from its current level.


Options:
A: Intervention Type: DRUG; Name: Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Micronutrient (Zinc and Iron) fortification; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Pre and Probiotic fortification; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Zinc and ORS | Arm Label: 2; Type: OTHER; Interventions: Drug: ORS only | Intervention Type: DRUG; Name: Zinc and ORS; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ORS only; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Zinc Supplementation in Low Birth Weight Infants on Severe Morbidity, Mortality and Zinc Status: A Randomized Controlled Trial
Brief Summary: There are currently no interventions available to substantially reduce the incidence of low birth weight (LBW) apart from increasing the age at marriage, maternal iron supplementation and possibly improved energy intakes.

The current view of the medical and public health community in India is that the immediate focus should be on promoting survival and development of low birth weight infants who have nearly a 6 to 7 fold higher mortality during infancy than those with normal birth weight.

Low serum zinc is associated with increased incidence of diarrhea and pneumonia. There is sufficient evidence in under-threes that during acute illness, zinc supplementation (1-2 recommended dietary allowance \[RDA\]) reduces incidence of all episodes of diarrhea, severe diarrhea and pneumonia. A number of initial published trials also show significant effect of zinc treatment on pneumonia. With the large and consistent effects of zinc supplementation on the incidence and severity of infections, an effect on child mortality is likely.

Available literature suggests the distinct possibility of reduced neonatal and infant mortality in LBWs receiving 1 RDA of zinc daily. A pilot study in India showed a 54% reduction in mortality in LBW infants. These findings were based on a very small sample and therefore considered insufficient to change policy.

A positive impact in the proposed study will provide an important tool for reduction of infant mortality which is currently stagnant and government acceptance for such a program is likely to be very high. We, the researchers at the Society for Applied Studies, believe this study has the potential for decreasing infant mortality from its current level.


Options:
A: Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Drug: Multivitamins | Arm Label: Multivitamins + Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc, Drug: Multivitamins | Arm Label: Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): Multivitamins + Zinc, Zinc | Intervention Type: DRUG; Name: Multivitamins; Assigned to Arm(s): Multivitamins, Multivitamins + Zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: zinc sulphate dietary supplement; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iron sulphate-folic acid dietary supplement; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Antibiotic Prescriptions in Respiratory Tract Infections be Improved? A Cluster Randomized Educational Intervention in General Practice
Brief Summary: This study will explore the possible effect of a tailored educational intervention towards general practitioners, in order to improve antibiotic prescriptions for respiratory infections.


Options:
A: Intervention Type: BEHAVIORAL; Name: Educational intervention; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Educational intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Educational intervention program; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Fall Prevention Tool Kit prototype using a randomized design | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Fall Prevention Tool Kit prototype using a randomized design; Assigned to Arm(s): 1
D: Intervention Type: BEHAVIORAL; Name: safety program; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Antibiotic Prescriptions in Respiratory Tract Infections be Improved? A Cluster Randomized Educational Intervention in General Practice
Brief Summary: This study will explore the possible effect of a tailored educational intervention towards general practitioners, in order to improve antibiotic prescriptions for respiratory infections.


Options:
A: Intervention Type: BEHAVIORAL; Name: Educational intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Educational intervention program; Assigned to Arm(s): N/A
B: Arm Label: C-reactive protein test; Type: EXPERIMENTAL; Interventions: Device: C-reactive protein test | Intervention Type: DEVICE; Name: C-reactive protein test; Assigned to Arm(s): C-reactive protein test
C: Arm Label: UltraPro; Type: EXPERIMENTAL; Interventions: Diagnostic Test: UltraPro, Diagnostic Test: Blood sampling, Diagnostic Test: Naso-pharyngeal swab and sputum culture | Arm Label: Procalcitonin; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Procalcitonin, Diagnostic Test: Blood sampling, Diagnostic Test: Naso-pharyngeal swab and sputum culture | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Naso-pharyngeal swab and sputum culture | Intervention Type: DIAGNOSTIC_TEST; Name: UltraPro; Assigned to Arm(s): UltraPro | Intervention Type: DIAGNOSTIC_TEST; Name: Procalcitonin; Assigned to Arm(s): Procalcitonin | Intervention Type: DIAGNOSTIC_TEST; Name: Blood sampling; Assigned to Arm(s): Procalcitonin, UltraPro | Intervention Type: DIAGNOSTIC_TEST; Name: Naso-pharyngeal swab and sputum culture; Assigned to Arm(s): Procalcitonin, UltraPro, Usual Care
D: Intervention Type: OTHER; Name: laboratory value procalcitonin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Antibiotic Prescriptions in Respiratory Tract Infections be Improved? A Cluster Randomized Educational Intervention in General Practice
Brief Summary: This study will explore the possible effect of a tailored educational intervention towards general practitioners, in order to improve antibiotic prescriptions for respiratory infections.


Options:
A: Intervention Type: PROCEDURE; Name: Quality Initiative in Rectal Cancer (QIRC) strategy; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Educational intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Educational intervention program; Assigned to Arm(s): N/A
C: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention
D: Arm Label: Implementation intervention; Type: EXPERIMENTAL; Interventions: Other: Implementation intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation intervention; Assigned to Arm(s): Implementation intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aspirin/Folate Prevention of Large Bowel Polyps
Brief Summary: This is a randomized controlled trial of aspirin and/or folate supplementation for the prevention of the recurrence of neoplastic polyps (adenomas) of the large bowel.


Options:
A: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Folate; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Folic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin B12; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin B6; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: consumption of fortified bread; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aspirin/Folate Prevention of Large Bowel Polyps
Brief Summary: This is a randomized controlled trial of aspirin and/or folate supplementation for the prevention of the recurrence of neoplastic polyps (adenomas) of the large bowel.


Options:
A: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Folate; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ferrous fumarate (iron), Dietary Supplement: folic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Ferrous fumarate (iron); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): 1, 2
C: Arm Label: Multiple micronutrient - 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple Micronutrient | Arm Label: Iron and folic acid - 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Iron and Folic Acid | Arm Label: Folic Acid - 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic Acid | Arm Label: Multiple Micronutrient - 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple Micronutrient | Arm Label: Iron and Folic Acid - 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Iron and Folic Acid | Arm Label: Folic acid - 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic Acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple Micronutrient; Assigned to Arm(s): Multiple Micronutrient - 2, Multiple micronutrient - 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron and Folic Acid; Assigned to Arm(s): Iron and Folic Acid - 2, Iron and folic acid - 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid; Assigned to Arm(s): Folic Acid - 1, Folic acid - 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: "video doctor," computer module | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: "video doctor," computer module | Intervention Type: BEHAVIORAL; Name: "video doctor," computer module; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aspirin/Folate Prevention of Large Bowel Polyps
Brief Summary: This is a randomized controlled trial of aspirin and/or folate supplementation for the prevention of the recurrence of neoplastic polyps (adenomas) of the large bowel.


Options:
A: Intervention Type: PROCEDURE; Name: consumption of fortified bread; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Folate; Assigned to Arm(s): N/A
C: Arm Label: corn-soy-blend; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: corn-soy blend, Dietary Supplement: iron, Dietary Supplement: folic acid | Arm Label: corn-soy-blend + multiple micronutrients; Type: EXPERIMENTAL; Interventions: Dietary Supplement: corn-soy blend, Dietary Supplement: UNIMMAP | Arm Label: ready-to-use supplementary food; Type: EXPERIMENTAL; Interventions: Dietary Supplement: ready-to-use supplementary food | Intervention Type: DIETARY_SUPPLEMENT; Name: ready-to-use supplementary food; Assigned to Arm(s): ready-to-use supplementary food | Intervention Type: DIETARY_SUPPLEMENT; Name: corn-soy blend; Assigned to Arm(s): corn-soy-blend, corn-soy-blend + multiple micronutrients | Intervention Type: DIETARY_SUPPLEMENT; Name: iron; Assigned to Arm(s): corn-soy-blend | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): corn-soy-blend | Intervention Type: DIETARY_SUPPLEMENT; Name: UNIMMAP; Assigned to Arm(s): corn-soy-blend + multiple micronutrients
D: Arm Label: Folic acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Arm Label: L-5-MTHF; Type: EXPERIMENTAL; Interventions: Dietary Supplement: L-5-MTHF | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: L-5-MTHF; Assigned to Arm(s): L-5-MTHF | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aspirin/Folate Prevention of Large Bowel Polyps
Brief Summary: This is a randomized controlled trial of aspirin and/or folate supplementation for the prevention of the recurrence of neoplastic polyps (adenomas) of the large bowel.


Options:
A: Arm Label: Folic acid; Type: OTHER; Interventions: Dietary Supplement: Folic acid | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Folic acid | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ferrous fumarate (iron), Dietary Supplement: folic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Ferrous fumarate (iron); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: Nutritional supplements; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Folate; Assigned to Arm(s): N/A

Answer: D